TB-500

1. What is it?

In FDA documentation, TB-500 is a synthetic fragment of seven amino acids derived from a larger molecule called thymosin beta-4. It also has a specific chemical modification. Full-length thymosin beta-4 is a different substance. This distinction affects the interpretation of every paper: before treating a study as evidence about TB-500, we need to check what was actually tested. A similar name, shared origin and part of the same sequence do not guarantee identical effects. [163] [166]

2. Why do people turn to it?

TB-500 mainly appears in healing and recovery discussions. Evidence is insufficient to present it as proven treatment for torn tendons, overworked muscles or damaged joints. Studies of the related full-length molecule also cover other organs, such as the eye surface. This different use does not answer whether an athlete's functioning improves. Tissue, disease, product and method all differ. [166] [165]

3. How does it work?

Interest in this fragment stems from the properties of the larger thymosin beta-4 molecule and processes involved in cell movement and repair. This supports further experiments, but leaves many questions about TB-500 itself. Chemical studies can confirm a molecule's structure, but do not measure pain, muscle strength or time to recovery. An effect on cells in a laboratory dish also does not prove that the substance will reach damaged tissue in the body and rebuild it. [163] [166]

4. What do studies actually show?

A small eye study of RGN-259 enrolled 18 patients with a disease that damages the eye's surface. It tested eye drops containing full-length thymosin beta-4. There were signs of improved healing, but the small number of participants limits confidence in the conclusions, and the primary outcome did not provide conclusive confirmation. The key point for readers is that this was not a study of TB-500 for muscle recovery. Its results cannot be transferred to a short fragment sold under another name. This remains true when both compounds are described as thymosin: an abbreviated name does not remove the difference between a whole molecule and a fragment. [165]

5. What do we still not know?

Product naming creates another problem. Laboratory analyses have found differences between labels and actual contents in some products. This does not mean every product is the same or has the wrong composition. It means the label TB-500 alone cannot reliably connect a product to a publication. Without identifying the substance, we cannot even know whether a finding concerns the right molecule, regardless of other weaknesses in the evidence. Checking composition addresses only the first issue. Even a correctly identified fragment needs separate human studies of health benefits and safety. [164]

6. What are the risks?

FDA's 2026 assessment states that fragment safety data are insufficient. Studies of other peptides cannot establish reliable complication frequencies. Immune reactions and impurities may matter, and absent good risk data do not mean absent risk. Positive observations with eye products containing full-length thymosin do not establish safety for a different substance used another way. [166] [165]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [193]

7. Is it an approved medicine?

According to the cited FDA assessment, the TB-500 fragment is not an ingredient in a US-approved medicine. There is no basis for presenting it as an approved injury treatment in Poland. Research or approval of full-length thymosin beta-4 for another use does not automatically change the fragment's status. Assessing a compounding ingredient is not drug approval either. [166]

8. What is new in research?

A detailed FDA assessment in 2026 specifically addressing the TB-500 fragment helped clarify the evidence. It shows why compounds and products under this name must first be distinguished. Reviewed sources do not support announcing a new proven regenerative treatment for humans. Future reports should be checked for the full substance name, participants and actual outcomes before being treated as a TB-500 breakthrough. [166] [164]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.